TDM-Guided Ustekinumab Optimization Shows Superior Long-Term Efficacy in Crohn's Disease Maintenance Therapy
核心洞察
A multicenter Chinese study of 158 Crohn's disease (搜索) patients demonstrated that therapeutic drug monitoring (TDM)-guided ustekinumab optimization achieved significantly higher clinical remission rates at 2 years compared to standard therapy (71.3% vs 46.5%).
Patients receiving TDM-guided treatment maintained ustekinumab trough levels ≥3.0 μg/mL through weight-based intravenous reinduction when levels dropped below this threshold, resulting in superior treatment retention rates of 86.2% versus 49.3%.
The optimization strategy proved effective even in patients with baseline endoscopic response or mucosal healing, significantly reducing disease relapse rates over the 2-year follow-up period.
A multicenter retrospective study from China provides compelling evidence that therapeutic drug monitoring (TDM)-guided optimization of ustekinumab maintenance therapy significantly improves long-term clinical outcomes in patients with moderate-to-severe Crohn's disease (搜索) who have achieved clinical remission.
The study, conducted across three IBD centers in Hubei Province between October 2020 and November 2024, enrolled 158 patients with moderate-to-severe CD who had achieved clinical remission following ustekinumab induction therapy. Patients were stratified into TDM-guided optimization therapy (n=87) and standard therapy groups (n=71), with all participants followed for 2 years without corticosteroid therapy.
TDM-Guided Protocol Maintains Higher Drug Levels
The TDM protocol involved systematic monitoring of serum ustekinumab trough levels with dosing adjustments based on a 3.0 μg/mL threshold. Patients with trough levels ≥3.0 μg/mL continued subcutaneous 90 mg every 8 weeks, while those below this threshold received weight-based intravenous reinduction (260 mg for ≤55 kg; 390 mg for 55-85 kg; 520 mg for >85 kg patients).
This approach successfully maintained significantly higher trough concentrations throughout the maintenance period. At year 1, TDM patients achieved median trough levels of 3.00 μg/mL (IQR, 1.62-4.64) compared to 1.46 μg/mL (IQR, 0.12-3.25) in the standard therapy group (p<0.001). The difference persisted at year 2, with TDM patients maintaining 2.72 μg/mL (IQR, 1.19-4.61) versus 0.89 μg/mL (IQR, 0.36-1.16) in controls (p<0.001).
Superior Clinical Remission and Treatment Retention
The clinical benefits of TDM-guided optimization were substantial and sustained. At year 1, TDM patients maintained clinical remission at a rate of 83.9% (73/87) compared to 70.4% (50/71) in the standard therapy group (p=0.042). This advantage became more pronounced at year 2, with 71.3% (62/87) of TDM patients remaining in clinical remission versus only 46.5% (33/71) of standard therapy patients (p=0.002).
Treatment retention rates strongly favored the TDM approach, with 86.2% (75/87) of patients continuing ustekinumab therapy at 2 years compared to 49.3% (35/71) in the standard therapy group (p<0.001). TDM-guided treatment also significantly reduced disease relapse rates over the study period (p=0.003).
Benefits Extend to Patients with Endoscopic Response
Subgroup analyses revealed that TDM benefits extended even to patients with favorable baseline endoscopic outcomes. Among 57 TDM patients and 60 standard therapy patients who demonstrated endoscopic response at baseline, the TDM group achieved significantly higher clinical remission rates at year 2: 77.2% (44/57) versus 55.0% (33/60) (p=0.011).
Similarly, among patients with mucosal healing at baseline (50 TDM, 53 standard therapy), the TDM group demonstrated superior year 2 remission rates of 84.0% (42/50) compared to 64.2% (34/53) in the standard therapy group (p=0.022).
Optimized Dosing Strategy Reduces IV Requirements
The TDM protocol required an average of 2.1±0.5 intravenous ustekinumab doses in the first year, which significantly decreased to 1.8±0.8 doses in the second year (p=0.018), suggesting improved pharmacokinetic stability over time. Importantly, no anti-ustekinumab antibodies were detected in either group during follow-up, and no severe adverse events were reported.
Ustekinumab Shows Promise in Pouch-Related Crohn's Disease
In a separate multicenter study published in Inflammatory Bowel Diseases, researchers evaluated ustekinumab and vedolizumab efficacy in 104 adults who developed Crohn's disease (搜索) of the pouch following ileal pouch-anal anastomosis for ulcerative colitis (搜索). The retrospective cohort included 77 ustekinumab-treated and 57 vedolizumab-treated patients between 2011 and 2021.
Ustekinumab demonstrated superior clinical response rates at both 3 months (32% vs 18% for vedolizumab) and 6 months (29% vs 21%). Multivariable analyses revealed that ustekinumab patients had significantly higher likelihood of clinical response at 3 months (OR=2.73; 95% CI, 1.13-6.56) and 6 months (OR=2.53; 95% CI, 1.01-6.29) compared to vedolizumab.
Treatment durability strongly favored ustekinumab, with significantly longer treatment retention over 3-year follow-up (log rank p=0.005). Both therapies demonstrated acceptable safety profiles, with ustekinumab-related adverse events including arthralgias, hair loss, syncope, and upper respiratory infections, while vedolizumab was associated with wrist edema and elevated transaminases.
Clinical Implications for Maintenance Therapy
These findings address a critical gap in Crohn's disease (搜索) management, where real-world data show approximately half of patients fail to achieve clinical remission after one year of standard ustekinumab maintenance therapy. The SUCCESS Consortium data revealed that only 34.4% of patients achieved clinical remission with standard 8-weekly dosing, with annual secondary loss of response rates reaching 21%.
The Chinese study's TDM approach, targeting trough levels ≥3.0 μg/mL, represents a practical strategy to optimize therapeutic outcomes. As study investigators noted, "TDM-guided optimized maintenance therapy with ustekinumab conferred substantial advantages in sustained clinical remission, even for patients with improved endoscopic outcomes."
The research provides evidence that systematic monitoring and adjustment of ustekinumab dosing based on serum trough levels can significantly improve long-term treatment outcomes in Crohn's disease (搜索) patients, potentially transforming maintenance therapy approaches in clinical practice.